Literature DB >> 10082243

Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity.

A M Redmond1, A Harkin, J P Kelly, B E Leonard.   

Abstract

Previously it was found that both acute and chronic antidepressant pre-treatment enhanced the locomotor hyperactivity induced by a challenge injection of the non-competitive NMDA receptor antagonist, dizocilpine (MK-801). In the present study the effects of acute and chronic antidepressant administration on phencyclidine (PCP)-induced locomotor hyperactivity were examined. Phencyclidine (PCP), a non-competitive NMDA receptor antagonist increased locomotor activity in rats. Fluoxetine given acutely increased and prolonged the PCP-induced locomotor hyperactivity, while citalopram, sertraline and paroxetine had no effect on the PCP-induced behavioural effect. Repeated treatment with fluoxetine, citalopram and paroxetine increased the PCP-induced locomotor hyperactivity. In contrast, chronic sertraline administration attenuated the locomotor response to a PCP challenge. These results indicate that these antidepressants which are presumed to have a similar pharmacological profile, differ in their ability to alter PCP-induced hyperactivity. Whether these differences have any bearing on the therapeutic or adverse effects of these drugs remains to be shown.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10082243     DOI: 10.1016/s0924-977x(98)00023-6

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  7 in total

1.  Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice.

Authors:  Qi Zhang; Fei Guo; Zhi-wen Fu; Bing Zhang; Cheng-gang Huang; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2015-12-21       Impact factor: 6.150

2.  Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion.

Authors:  Changjiu Zhao; Tao Sun; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-03-26       Impact factor: 5.067

3.  Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity.

Authors:  Rongyin Qin; Yingzhu Chen; Ming Li
Journal:  Neuropharmacology       Date:  2013-08-14       Impact factor: 5.250

4.  Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.

Authors:  Qing Shu; Gang Hu; Ming Li
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

5.  Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Authors:  Qing Shu; Rongyin Qin; Yingzhu Chen; Gang Hu; Ming Li
Journal:  Behav Brain Res       Date:  2014-08-02       Impact factor: 3.332

6.  Effect of environmental cues on the behavioral efficacy of haloperidol, olanzapine, and clozapine in rats.

Authors:  Tao Sun; Xinfeng Liu; Ming Li
Journal:  Behav Pharmacol       Date:  2014-08       Impact factor: 2.293

7.  Effects of developmental exposure to manganese and/or low iron diet: Changes to metal transporters, sucrose preference, elevated zero-maze, open-field, and locomotion in response to fenfluramine, amphetamine, and MK-801.

Authors:  Robyn M Amos-Kroohs; Colin P Bloor; Momina A Qureshi; Charles V Vorhees; Michael T Williams
Journal:  Toxicol Rep       Date:  2015
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.